Anti-Fibrinolytic Drugs - Nepal

Nepal

In Nepal, the revenue in the Anti-Fibrinolytic Drugs market is estimated to reach US$2.91m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 5.54%, leading to a market volume of US$3.81m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$9,858.00m in 2024.
In Nepal, there is an increasing demand for anti-fibrinolytic drugs due to the rising incidence of hemorrhagic disorders in the population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in Nepal has been increasing steadily over the years.

Customer preferences: Nepal has a high incidence of bleeding disorders such as hemophilia and von Willebrand disease. These conditions require the use of Anti-Fibrinolytic Drugs to manage bleeding episodes. Additionally, there has been an increase in the number of surgeries performed in the country, which also drives the demand for these drugs.

Trends in the market: The Anti-Fibrinolytic Drugs market in Nepal is dominated by tranexamic acid, which is the most commonly used drug in the country. This drug is available in both oral and injectable forms. There has been a shift towards the use of injectable forms of the drug due to their faster onset of action and greater efficacy.

Local special circumstances: One of the unique challenges in Nepal is the lack of access to healthcare in remote areas. This means that patients with bleeding disorders may not receive timely treatment, which can result in serious complications. There is a need for greater awareness about these conditions and the availability of treatment options.

Underlying macroeconomic factors: Nepal is a low-income country with a relatively small healthcare market. However, the government has been investing in healthcare infrastructure and there has been a gradual increase in healthcare spending. This is expected to drive the growth of the Anti-Fibrinolytic Drugs market in the country. Additionally, there is a growing trend towards the use of generic drugs, which is likely to increase the availability and affordability of Anti-Fibrinolytic Drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.